CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 14.69 Billion USD | -24.99% |
| 2023 | 13.17 Billion USD | 25.55% |
| 2022 | 10.49 Billion USD | 2.22% |
| 2021 | 10.26 Billion AUD | 12.8% |
| 2020 | 9.1 Billion AUD | 6.94% |
| 2019 | 8.5 Billion AUD | 12.15% |
| 2018 | 7.58 Billion AUD | 14.69% |
| 2017 | 6.61 Billion AUD | 11.95% |
| 2016 | 5.9 Billion AUD | 8.26% |
| 2015 | 5.45 Billion AUD | 2.32% |
| 2014 | 5.33 Billion AUD | 7.77% |
| 2013 | 4.95 Billion AUD | 9.11% |
| 2012 | 4.53 Billion AUD | 1.37% |
| 2011 | 4.47 Billion AUD | 18.18% |
| 2010 | 3.78 Billion AUD | 1.51% |
| 2009 | 3.73 Billion AUD | 9.63% |
| 2008 | 3.4 Billion AUD | 26.46% |
| 2007 | 2.69 Billion AUD | 27.28% |
| 2006 | 2.11 Billion AUD | 0.82% |
| 2005 | 2.09 Billion AUD | 81.29% |
| 2004 | 1.15 Billion AUD | 31.64% |
| 2003 | 878.65 Million AUD | 16.13% |
| 2002 | 756.58 Million AUD | -10.28% |
| 2001 | 843.3 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | -100.0% |
| 1997 | 318.09 Million AUD | 13.16% |
| 1996 | 281.1 Million AUD | 12.25% |
| 1995 | 250.43 Million AUD | 29.76% |
| 1994 | 192.99 Million AUD | 15.09% |
| 1993 | 167.69 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 6.64 Billion USD | 0.0% |
| 2024 FY | 14.69 Billion USD | 11.51% |
| 2024 Q1 | 6.26 Billion USD | 4.46% |
| 2024 Q2 | 8.01 Billion USD | 0.0% |
| 2023 Q1 | 5.61 Billion USD | 24.18% |
| 2023 FY | 13.17 Billion USD | 25.55% |
| 2023 Q4 | 5.99 Billion USD | 30.86% |
| 2023 Q3 | 4.58 Billion USD | -35.93% |
| 2023 Q2 | 7.15 Billion USD | 27.35% |
| 2022 Q4 | 4.52 Billion USD | 49.73% |
| 2022 Q2 | 6.01 Billion USD | 43.8% |
| 2022 FY | 10.49 Billion USD | 2.22% |
| 2022 Q3 | 3.02 Billion USD | -49.75% |
| 2022 Q1 | 4.17 Billion USD | -4.81% |
| 2021 Q4 | 4.39 Billion USD | 45.95% |
| 2021 Q3 | 3 Billion USD | -47.44% |
| 2021 Q1 | 4 Billion USD | -7.08% |
| 2021 Q2 | 5.72 Billion USD | 42.8% |
| 2021 FY | 10.26 Billion AUD | 12.8% |
| 2020 Q4 | 4.31 Billion USD | 25.13% |
| 2020 FY | 9.1 Billion AUD | 6.94% |
| 2020 Q2 | 4.87 Billion USD | 34.04% |
| 2020 Q1 | 3.63 Billion USD | -10.59% |
| 2020 Q3 | 3.44 Billion USD | -29.3% |
| 2019 Q3 | 2.84 Billion USD | -11.17% |
| 2019 FY | 8.5 Billion AUD | 12.15% |
| 2019 Q1 | 3.11 Billion USD | 22.41% |
| 2019 Q4 | 4.06 Billion AUD | 43.23% |
| 2019 Q2 | 3.19 Billion USD | 2.61% |
| 2018 Q2 | 2.65 Billion USD | 0.5% |
| 2018 Q3 | 2.45 Billion USD | -7.68% |
| 2018 Q4 | 2.54 Billion AUD | 3.8% |
| 2018 FY | 7.58 Billion AUD | 14.69% |
| 2018 Q1 | 2.64 Billion USD | 24.25% |
| 2017 Q2 | 2.54 Billion USD | 6.07% |
| 2017 Q1 | 2.4 Billion USD | 20.09% |
| 2017 FY | 6.61 Billion AUD | 11.95% |
| 2017 Q4 | 2.12 Billion AUD | -0.6% |
| 2017 Q3 | 2.14 Billion USD | -15.98% |
| 2016 Q3 | 1.93 Billion USD | -9.96% |
| 2016 Q4 | 1.99 Billion AUD | 3.17% |
| 2016 FY | 5.9 Billion AUD | 8.26% |
| 2016 Q2 | 2.15 Billion USD | -3.47% |
| 2016 Q1 | 2.23 Billion USD | 26.46% |
| 2015 Q3 | 1.77 Billion USD | 6.13% |
| 2015 Q2 | 1.67 Billion USD | 6.9% |
| 2015 Q1 | 1.56 Billion USD | 7.16% |
| 2015 FY | 5.45 Billion AUD | 2.32% |
| 2015 Q4 | 1.76 Billion AUD | -0.9% |
| 2014 Q3 | 1.48 Billion USD | 3.44% |
| 2014 FY | 5.33 Billion AUD | 7.77% |
| 2014 Q1 | 1.37 Billion USD | 2.15% |
| 2014 Q4 | 1.46 Billion AUD | -1.69% |
| 2014 Q2 | 1.43 Billion USD | 4.51% |
| 2013 FY | 4.95 Billion AUD | 9.11% |
| 2013 Q2 | 1.19 Billion USD | -0.06% |
| 2013 Q4 | 1.34 Billion AUD | 13.7% |
| 2013 Q1 | 1.19 Billion USD | 0.0% |
| 2013 Q3 | 1.18 Billion USD | -0.82% |
| 2012 FY | 4.53 Billion AUD | 1.37% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | 4.47 Billion AUD | 18.18% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 3.78 Billion AUD | 1.51% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 3.73 Billion AUD | 9.63% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 3.4 Billion AUD | 26.46% |
| 2007 FY | 2.69 Billion AUD | 27.28% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 2.11 Billion AUD | 0.82% |
| 2005 FY | 2.09 Billion AUD | 81.29% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | 1.15 Billion AUD | 31.64% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | 878.65 Million AUD | 16.13% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | 756.58 Million AUD | -10.28% |
| 2001 FY | 843.3 Million AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | -100.0% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | 318.09 Million AUD | 13.16% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | 281.1 Million AUD | 12.25% |
| 1995 FY | 250.43 Million AUD | 29.76% |
| 1994 FY | 192.99 Million AUD | 15.09% |
| 1993 FY | 167.69 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -19399297.813% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -80534.537% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -11847.575% |
| Qrons Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -760251.967% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -93033.836% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -83366337.773% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -68295.568% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -22349583.544% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -248798.678% |
| Marizyme, Inc. | 645.81 Thousand USD | -2274562.827% |
| Genus plc | 668.8 Million USD | -2096.471% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -5888.195% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -14839183.189% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3581385.5% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -19137222.338% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -37172833.853% |
| MultiCell Technologies, Inc. | 49.32 USD | -29785076947.851% |
| ONE Bio Corp. | 52.29 Million USD | -27989.993% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -29444.86% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -30040799.796% |
| Q BioMed Inc. | 284.35 Thousand USD | -5166032.118% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -49533.409% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -10024.078% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -2633885.405% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -20985614.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -2230727.639% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -1470470370.47% |
| Enzolytics Inc. | 52.79 Thousand USD | -27823977.582% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -2413933.935% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -1097.897% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -10474650.788% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2379294.348% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -1649.791% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -1472248.12% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -30280.113% |
| BioStem Technologies, Inc. | 16.68 Million USD | -87941.015% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6209741.055% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6209741.055% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1072946.019% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -3100822.466% |
| SYBLEU INC | 11.69 Thousand USD | -125598395.212% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -188499.307% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -112999900.0% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -37157789.412% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -441041.141% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -220305.101% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -1413759.48% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -56910.905% |
| CSL Limited | 14.8 Billion USD | 0.743% |
| Cellectis S.A. | 755 Thousand USD | -1945595.364% |